2017_SBRT_Course Book

Multi-center analysis: King et al Radiat Oncol 2013

Risk-group Follow- up Low 36 mo Intermediate 31 mo High 23 mo 1100 patients 8 institutions All patients enrolled in phase II studies

Ø Promising results in all risk groups but FU still short Ø Very few patients in the high-risk group and no further information about detailed risk

Matthias Guckenberger - ESTRO SBRT Course 2017

07.09.17

/ 25

/

Antihormonal therapy in SBRT

CF-RT with >76Gy

MVA in prostate SBRT

Zapatero Lancet Oncol 2015

King Radiat Oncol 2015

Ø No clear recommendation possible Ø Most centers practice SBRT for intermediate risk w/o antihormonal therapy

Matthias Guckenberger - ESTRO SBRT Course 2017

07.09.17

/ 26

/